Binding of the Fap2 Protein of Fusobacterium nucleatum to Human Inhibitory Receptor TIGIT Protects Tumors from Immune Cell Attack
Chamutal Gur(Hebrew University of Jerusalem), Yara Ibrahim(Hebrew University of Jerusalem), Batya Isaacson(Hebrew University of Jerusalem), Rachel Yamin(Hebrew University of Jerusalem), Jawad Abed(Hebrew University of Jerusalem), Moriya Gamliel(Hebrew University of Jerusalem), Jonatan Enk(Hebrew University of Jerusalem), Yotam Bar‐On(Hebrew University of Jerusalem), Noah Stanietsky-Kaynan(Hebrew University of Jerusalem), Shunit Coppenhagen‐Glazer(Hebrew University of Jerusalem), Noam Shussman(Hadassah Medical Center), Gideon Almogy(Hadassah Medical Center), Angélica Cuapio(Medical University of Vienna), Erhard Hofer(Medical University of Vienna), Dror Mevorach(Hebrew University of Jerusalem), Adi Tabib(Hebrew University of Jerusalem), Rona Ortenberg(Sheba Medical Center), Gal Markel(Sheba Medical Center), Karmela Miklić(University of Rijeka), Stipan Jonjić(University of Rijeka), Caitlin A. Brennan(Harvard University), Wendy S. Garrett(Harvard University), Gilad Bachrach(Hebrew University of Jerusalem), Ofer Mandelboim(Hebrew University of Jerusalem)
Cited by 1,409Open Access
Abstract
Related Papers
The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity
Noa Stanietsky, Hrvoje Šimić, Jurica Arapović et al.|Proceedings of the National Academy of Sciences|2009|3.5k